ProQR Therapeutics N.V.
$1.84
0%
2026-04-21 08:57:01
www.proqr.com
NCM: PRQR
Explore ProQR Therapeutics N.V. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$206.51 M
Current Price
$1.84
52W High / Low
$3.1 / $1.1
Stock P/E
—
Book Value
$0.54
Dividend Yield
—
ROCE
-54.09%
ROE
-61.17%
Face Value
—
EPS
$-0.47
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
186
Beta
0.09
Debt / Equity
32.33
Current Ratio
3.09
Quick Ratio
3.09
Forward P/E
-3.94
Price / Sales
11.92
Enterprise Value
$118.47 M
EV / EBITDA
-2.79
EV / Revenue
7.25
Rating
Strong Buy
Target Price
$8.88
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Nuvation Bio Inc. | $5.12 | — | $1.77 B | — | -41.57% | -53.18% | $9.75 / $1.57 | $0.88 |
| 2. | OKYO Pharma Limited | $1.59 | — | $85.27 M | — | 127.79% | 82.36% | $3.35 / $1.11 | $-0.09 |
| 3. | Scholar Rock Holding Corporation | $47.8 | — | $5.49 B | — | -110.26% | -1.23% | $51.62 / $27.07 | $2.26 |
| 4. | Heron Therapeutics, Inc. | $1.05 | — | $187.09 M | — | -1.59% | 209.08% | $2.61 / $0.74 | $0.07 |
| 5. | LENZ Therapeutics, Inc. | $10.13 | — | $319.19 M | — | -32.01% | -33.63% | $50.4 / $8.25 | $9.07 |
| 6. | Monte Rosa Therapeutics, Inc. | $19.81 | — | $1.58 B | — | -14.1% | -16.94% | $25.77 / $3.51 | $3.56 |
| 7. | Silo Pharma, Inc. | $0.67 | — | $8.38 M | — | -61.55% | -74.57% | $1.19 / $0.22 | $0.47 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 4.69 M | 2.88 M | 3.82 M | 4.52 M | 4.31 M | — |
| Operating Profit | -9.1 M | -11.28 M | -12.25 M | -10.82 M | -10.08 M | — |
| Net Profit | -8.92 M | -11.01 M | -12.18 M | -10.08 M | -9.3 M | — |
| EPS in Rs | -0.08 | -0.1 | -0.12 | -0.1 | -0.09 | -0.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 15.91 M | 18.91 M | 6.51 M | 3.59 M |
| Operating Profit | -43.45 M | -30.47 M | -34.79 M | -65.16 M |
| Net Profit | -42.18 M | -27.76 M | -28.12 M | -64.42 M |
| EPS in Rs | -0.4 | -0.26 | -0.27 | -0.61 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 112.76 M | 167.96 M | 137.88 M | 171.32 M |
| Total Liabilities | 63.38 M | 79.4 M | 96.49 M | 104.64 M |
| Equity | 49.37 M | 88.56 M | 41.39 M | 67.06 M |
| Current Assets | 100.13 M | 153.84 M | 120.99 M | 154.46 M |
| Current Liabilities | 32.44 M | 38.9 M | 34.2 M | 20.99 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -52.79 M | -36.39 M | 21.55 M | -68.51 M |
| Investing CF | -1.02 M | -4.07 M | 4.28 M | -0.7 M |
| Financing CF | -1.84 M | 70.28 M | -2.27 M | -30.89 M |
| Free CF | -53.81 M | -37.81 M | 20.18 M | -69.22 M |
| Capex | -1.02 M | -1.42 M | -1.37 M | -0.71 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 190.22% | 81.25% | — | — |
| Earnings Growth % | 1.27% | 56.35% | — | — |
| Profit Margin % | -146.86% | -431.67% | -1792.54% | — |
| Operating Margin % | -161.18% | -534.08% | -1812.99% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -127.6% | -369.93% | -1570.95% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.